National Comprehensive Cancer Network

NCCN Global

Asia

 

Global Initiatives

The National Comprehensive Cancer Network® (NCCN®) is dedicated to improving high-quality, high-value cancer care around the globe, including through various collaborations to promote translations and adaptations of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for use in Asia.

NCCN has a significantly active presence in Asia with more than 200,000 registered oncology professionals and more than 700,000 NCCN Guidelines® downloaded in 2017.

NCCN has an ongoing collaboration with Reno Medical to publish regional adaptations of the NCCN Guidelines for use in Asia. Adaptations of the NCCN Guidelines are developed by the host country's oncology thought leaders in conjunction with NCCN Guidelines Panel members. Modified NCCN Guidelines are developed to aid clinicians in determining appropriate and efficient avenues of care in the specified country. Participants include NCCN Guidelines Panel members and a panel of multidisciplinary specialists from China, Japan, South Korea, and Taiwan, who engage in consensus discussions. These adaptations, the Asia Consensus Statements, are English-language manuscripts designed to provide clinical resources for Asian specialists who are involved in the management of cancer patients within the represented countries.

View Asia Consensus Statement (ACS) adaptations


China

Chinese translations of NCCN Guidelines are available on the International Adaptations & Translations page.

November 2017, Robert W. Carlson, MD, Chief Executive Officer, NCCN, was in Beijing, China for the International Forum for Quality Cancer Care, hosted by Oxford University to present on “The Development and Evolution of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)”.

NCCN has also made available a Chinese Website, a valuable online resource for clinical professionals and other health care decision-makers in China.

View the NCCN China Website


Israel

NCCN leadership and panel members attended the Israeli Society for Clinical Oncology and Radiation Therapy Annual Meeting (ISCORT 2018) in Eilat, Israel on 9 – 12 January 2018, and participated in several presentations and tumor specific workshops.

Representing NCCN were Robert W. Carlson, MD, Chief Executive Officer, NCCN, David S. Ettinger, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and James L. Mohler, MD, Roswell Park Comprehensive Cancer Center. Dr. Carlson discussed and presented major themes, including the NCCN Guidelines, the NCCN Evidence Blocks™, the NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™), and the NCCN Categories of Preference. Additionally, Dr. Carlson discussed the NCCN model for bringing evidence to practice. Dr. Ettinger delivered a pre-meeting workshop focusing on immunotherapy for Non-Small Cell Lung Cancer (NSCLC) and a presentation on the NCCN Guidelines for NSCLC. Dr. Mohler led a pre-meeting workshop on the NCCN Guidelines for Urologic Cancer and gave a presentation on the NCCN Guidelines for Prostate Cancer.

The ISCORT 2018 conference focused on all major topics in oncology and radiation therapy, and included novel studies, educational sessions, and multidisciplinary tumor boards. NCCN was delighted to attend the ISCORT 2018 conference. This opportunity was a springboard to increasing the global influence and demand for the NCCN Guidelines.


India

In November 2017, Robert W. Carlson, MD, Chief Executive Officer, NCCN, took part in the India Cancer Congress in Bengaluru, where he met with Dr. GK Rath, head of India’s National Cancer Institute.  His presentation, titled “NCCN Guidelines: Development, Uses, and Future Directions”, provided information on the NCCN Guidelines development process and their derivative products.


Japan

NCCN has consented to direct non-adapted translations of the Complete Library of NCCN Guidelines into Japanese by a major, national university in Kyoto, Japan. These translations are part of a large endeavor by Translational Research Informatics (TRI) to translate the Complete Library of NCCN Guidelines into non-adapted Japanese translations. Each translation of the NCCN Guidelines is managed by the appropriate medical society in Japan to ensure its accuracy for use by Japanese clinicians in the treatment of their patients.

Currently, there are 32 Japanese translations of NCCN Guidelines available on NCCN.org/global. The addition of these translations further strengthens NCCN's commitment to improving the quality, effectiveness, and efficiency of cancer care regardless of language or geographic barriers.

If you would like to learn more about translations, how to support translations and regional adaptations of the NCCN Guidelines, or other international programming opportunities, please contact Jorge Bacigalupo, Global Business Development Program Manager.

NCCN_Japan

The Japan Comprehensive Cancer Network, Breast (JCCNB) has worked with NCCN since June 2005 to translate the NCCN Guidelines for Breast Cancer into Japanese and to explain differences between treatment guidelines in Japan and the United States regarding breast cancer.

Continue to Japan Comprehensive Cancer Network - Breast (JCCNB) for information in Japanese.
乳がんに関する情報を日本語でご覧になりたい方は下記のリンクにて
日本乳がん情報ネットワークのホームページをアクセスして下さい。

JCCNB

View Japanese Translations on NCCN.org


South Korea

Korean translations of NCCN Guidelines are available on the International Adaptations & Translations page.


Visit the Global Initiatives page to learn more

We welcome the opportunity to explore potential collaborations with you.

If you have questions about NCCN international programs, please visit our Global Contact Page